A single-center, phase 1/2a trial of hESC-derived mesenchymal stem cells (MR-MC-01) for safety and efficacy in interstitial cystitis patients
Stem Cells Translational Medicine · 19.05.2025 · 14 (5)
DOI: 10.1093/stcltm/szaf018 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Stem Cells Translational Medicine, online erschienen am 19.05.2025. Verfasst von Yoon Soo Kyung und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea. Hauptthemen laut MEDLINE: Cystitis, Interstitial, Mesenchymal Stem Cell Transplantation, Mesenchymal Stem Cells, Human Embryonic Stem Cells. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
This study investigated the safety and efficacy of MR-MC-01, a mesenchymal stem cell therapy derived from human embryonic stem cells, in patients with interstitial cystitis (IC), particularly those with Hunner lesions unresponsive to pentosan polysulfate sodium (PPS). Conducted as a prospective, randomized, double-blind, placebo-controlled phase I/IIa clinical trial, it enrolled 22 patients, with six completing phase I and 16 participating in phase IIa. Phase I tested 2 doses (2.0 × 107 and 5.0 × 107 cells) to determine the maximum tolerated dose (MTD), revealing no dose-limiting toxicities and only mild adverse events such as transient hemorrhage and bladder pain. In phase IIa, 12 participants received the MTD of 5.0 × 107 cells, and 4 received placebo. Significant reductions in interstitial cystitis questionnaire (ICQ) and pain urgency frequency (PUF) scores were observed in the treatment group. Improvements were noted in nocturnal voiding frequency and Hunner lesion size, with 8 patients showing either a reduction or complete resolution of lesions after 6 months. The global response assessment (GRA) reported moderate to marked improvement in 41.67% of treated patients versus 25% in the placebo group. MR-MC-01 demonstrated no serious drug-related adverse events, highlighting its favorable safety profile. These findings suggest that MR-MC-01 not only alleviates symptoms but also promotes structural recovery in IC, making it a promising treatment option. Further large-scale, long-term studies are warranted to confirm these results and optimize therapeutic protocols. (Identifier: NCT04610359)
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea.
- Health Screening and Promotion Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea.
- Mirae Cell Bio Co., Ltd., Seoul 04795, Korea.
- Department of Stem Cell Biology, School of Medicine, Konkuk University, Seoul 05029, Korea.
- Department of Urology, Ewha Womans University, Mokdong Hospital, Seoul 07985, Korea.
- Doctor Joo Urology Clinic, Seoul 06060, Korea.
ORCID-Profile: Myung-Soo Choo, Juhyun Park
Zitieren
APA
Kyung, Y. S., Hong, K. S., Chung, H. M., Hyun Shin, J., Choo, M. S., Kim, E. Y., Shin, J. M., Kang, A. R., Seo, J. W., Park, J., & Park, S. P. (2025). A single-center, phase 1/2a trial of hESC-derived mesenchymal stem cells (MR-MC-01) for safety and efficacy in interstitial cystitis patients. Stem Cells Translational Medicine, 14(5). https://doi.org/10.1093/stcltm/szaf018
Vancouver
Kyung YS, Hong KS, Chung HM, Hyun Shin J, Choo MS, Kim EY, et al. A single-center, phase 1/2a trial of hESC-derived mesenchymal stem cells (MR-MC-01) for safety and efficacy in interstitial cystitis patients. Stem Cells Translational Medicine. 2025;14(5). doi:10.1093/stcltm/szaf018
BibTeX
@article{Kyung2025,
author = {Kyung, Yoon Soo and Hong, Ki-Sung and Chung, Hyung-Min and Hyun Shin, Jung and Choo, Myung-Soo and Kim, Eun-Young and Shin, Jeong Min and Kang, Ah Reum and Seo, Jin Won and Park, Juhyun and Park, Se-Pill},
title = {A single-center, phase 1/2a trial of hESC-derived mesenchymal stem cells (MR-MC-01) for safety and efficacy in interstitial cystitis patients},
journal = {Stem Cells Translational Medicine},
year = {2025},
volume = {14},
number = {5},
doi = {10.1093/stcltm/szaf018}
}
EUVIMED